Notwithstanding encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from managed care entities. Such companies are often erecting obstacles to reimbursement, like high cost restrictions and a